In recent years, new prospects for the use of nucleic acids as anticancer drugs have been discovered. Aptamers for intracellular targets can regulate cellular functions and cause cell death or proliferation. However, intracellular aptamers have limited use for therapeutic applications due to their low bioavailability. In this work, we selected DNA aptamers to cell organelles and nucleus of cancer cells, and showed that an aptamer NAS-24 binds to vimentin and causes apoptosis of mouse ascites adenocarcinoma cells in vitro and in vivo. To deliver the aptamer NAS-24 inside cells, natural polysaccharide arabinogalactan was used as a carrier reagent. The mixture of arabinogalactan and NAS-24 was injected intraperitonealy for 5 days into mice with adenocarcinoma and inhibited adenocarcinoma growth more effectively than free arabinogalactan or the aptamer alone. The use of aptamers to intracellular targets together with arabinogalactan becomes a promising approach for anticancer therapy.
Get full access to this article
View all access options for this article.
References
1.
AHMEDM., and NARAINR. (2012). Intracellular delivery of DNA and enzyme in active form using degradable carbohydrate-based nanogels. Mol. Pharm., 9, 3160–3170. DOI: 10.1021/mp300255p.
2.
AL-HENDYA., and SALAMAS. (2006). Gene therapy and uterine leiomyoma: a review. Hum. Reprod. Update, 12, 385–400.
3.
BEREZOVSKIM.V., LECHMANNM., MUSHEEVM.U., MAKT.W., and KRYLOVS.N. (2008). Aptamer-facilitated biomarker discovery (AptaBiD). J. Am. Chem. Soc., 130, 9137–9143.
4.
BYUNY., CHENF., CHANGR., TRIVEDIM., GREENK.J., CRYNSV.L. (2001). Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ., 8, 443–450.
5.
CAWLEYD.B., SIMPSOND.L., and HERSCHMANH.R. (1981). Asialoglycoprotein receptor mediates the toxic effects of an asialofetuin-diphtheria toxin fragment A conjugate on cultured rat hepatocytes. Proc. Nat. Acad. Sci. U. S. A., 78, 3383–3387.
6.
CHALLAA.A., and STEFANOVICB. (2011). A novel role of vimentin filaments: binding and stabilization of collagen mRNAs. Mol. Cell Biol., 31, 3773–3789.
7.
CHOIK., KIMK., KWONI.C., KIMI.S., and AHNH.J. (2012). Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity in vivo. Mol. Pharm. DOI: 10.1021/mp300211a.
8.
CODREAV., HAYNERM, HALLB., JHAVERIS., and ELLINGTONA. (2010). In vitro selection of RNA aptamers to a small molecule target. Curr. Prot. Nucleic Acid Chem. DOI:10.1002/0471142700.nc0905s40.
9.
COXJ., and MANNM. (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol., 26, 1367–1372.
10.
ELIYAHUH., BARENHOLZY., and DOMBA.J. (2005). Polymers for DNA delivery. Molecules, 10, 34–64.
11.
ELLINGTONA., and SZOSTAKJ. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature, 346, 818–822.
12.
FUYUHIROY., YASHIROM., NODAS., KASHIWAGIS., MATSUOKAJ., DOIY., KATOY., KUBON., OHIRAM., and HIRAKAWAK. (2010). Clinical significance of vimentin-positive gastric cancer cells. Anticancer Res., 30, 239–243.
13.
GABORF. B, OGNERE. W, EISSENBOECKA., and WIRTHM. (2004). The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv. Drug Deliv. Rev., 56, 459–480.
14.
GILLESC., POLETTEM., MESTDAGTM., NAWROCKI-RABYB., RUGGERIP., BIREMBAUTP., and FOIDARTJ.M. (2003). Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res., 63, 2658–2664.
15.
GROMANE.V., ENRIQUEZP.M., JUNGC., and JOSEPHSONL. (1994). Arabinogalactan for hepatic drug delivery. Bioconjug. Chem., 5, 547–556.
16.
HUL., LAUS.H., TZANGC.H., WENJ.M., WANGW., XIED., HUANGM., WANGY., WUM.C., HUANGJ.F., et al. (2004). Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene, 23, 298–302.
17.
HUANGY.F., SHANGGUAND., LIUH., PHILLIPSJ.A., ZHANGX., CHENY., and TANW. (2009). Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem, 10, 862–868.
18.
IVASKAJ., PALLARIH.M., NEVOJ., and ERIKSSONJ.E. (2007). Novel functions of vimentin in cell adhesion, migration, and signaling. Exp. Cell Res., 313, 2050–2062.
19.
JIANY, GAOZ, SUNJ, SHEN FENGQF, JINGY, YANGC. (2009). RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells. Oncogene, 28, 4201–4211.
20.
JINH., MOROHASHIS., SATOF., et al. (2010). Vimentin expression of esophageal squamous cell carcinoma and its aggressive potential for lymph node metastasis. Biomed. Res., 31, 105–112.
21.
JULIANOR., ALAMM.R., DIXITV., KANGH. (2008). Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res., 36, 4158–4171.
22.
KAZUKIY., HOSHIYAH., TAKIGUCHIM., ABES., IIDAY., OSAKIM., KATOHM., HIRATSUKAM., SHIRAYOSHIY., HIRAMATSUK., et al. (2011). Refined human artificial chromosome vectors for gene therapy and animal transgenesis. Gene Ther., 18, 384–393.
23.
KEEFEA.D., PAIS., and ELLINGTONA. (2010). Aptamers as therapeutics. Nat. Rev. Drug Discov., 9, 537–550.
24.
KOLOVSKAYAO.S., SAVITSKAYAA.G., ZAMAYT.N., RESHETNEVAI.T., ZAMAYG.S., et al. (2013). Development of bacteriostatic DNA aptamers for salmonella. J. Med. Chem., 56, 1564–1572.
25.
KORSCHINGE., PACKEISENJ., LIEDTKEC., HUNGERMANND., WULFINGP., VAN DIESTP.J., BRANDTB., BOECKERW., and BUERGERH. (2005). The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential. J. Pathol., 206, 451–457.
26.
LABIBM., ZAMAYA.S., MUHAREMAGICD., CHECHIKA., BELLJ.C., and BEREZOVSKIM.V. (2012). Electrochemical differentiation of epitope-specific aptamers. Anal. Chem., 84, 2548–2556.
27.
LAHATG., ZHUQ.S., HUANGK.L., WANGS., BOLSHAKOVAS., LIUJ., TORRESK., LANGLEYR.R., LAZARA.J., HUNGM.C. and LEVD. (2010). Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One, 5, e10105. DOI:10.1371/journal.pone.001010.
28.
LEHRC.M., and GABORF. (2004). Lectins and glycoconjugates in drug delivery and targeting. Adv. Drug Deliv. Rev., 56, 419–420.
29.
LIH., SUNX., ZHAOD., and ZHANGZ. (2012). A cell-specific poly(ethylene glycol) derivative with a wheat-like structure for efficient gene delivery. Mol. Pharm., 9, 2974–2985. DOI: 10.1021/mp300321n.
30.
LIM., ZHANGB., SUNB., WANGX., BANX., SUNT., LIUZ., and ZHAOX. (2010). A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis. J. Exp. Clin. Cancer Res. 29,109.
31.
LIN., NGUYENH.H., BYROMM., and ELLINGTONA.D. (2011). Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One, 6, e20299, 1–10.
32.
LIY., HUANGG., DIAKURJ., and WIEBEL.I. (2008). Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr. Drug Deliv., 5, 299–302.
33.
MEYERC., HAHNU., and RENTMEISTERA. (2011). Cell-specific aptamers as emerging therapeutics. J. Nucleic Acids, 2011, 904750. DOI:10.4061/2011/904750.
34.
MUHAREMAGICD., LABIBM., GHOBADLOOS.M., ZAMAYA.S., BELLJ.C., and BEREZOVSKIM.V. (2012). Anti-fab aptamers for shielding virus from neutralizing antibodies. J. Am. Chem. Soc., 134, 17168–17177.
35.
RAYP., and WHITER.R. (2010). Aptamers for targeted drug delivery. Pharmaceuticals, 3, 1761–1778.
36.
RHOJ.H., ROEHRLM.H., and WANGJ.Y. (2009). Glycoproteomic analysis of human lung adenocarcinomas using glycoarrays and tandem mass spectrometry: differential expression and glycosylation patterns of vimentin and fetuin A isoforms. Protein J., 28, 148–160.
37.
SATELLIA, LIS. (2011). Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol. Life Sci., 68, 3033–3046.
38.
SELLINSK., FRADKINL., LIGGITTD., and DOWS. (2005). Type I interferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes. Mol. Ther., 12, 451–459.
39.
SETHIS., MACOSKAJ., CHENW., and SARKARF.H. (2010). Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am. J. Transl. Res., 3, 90–99.
40.
STRIBLEYJ.M., REHMANK.S., NIUH., and CHRISTMANG.M. (2002). Gene therapy and reproductive medicine. Fertil. Steril., 77, 645–657.
TUERKC., and GOLDL. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249, 505–510.
43.
ULRICHH. (2006). RNA aptamers: from basic science towards therapy. Handb. Exp. Pharmacol., 173, 305–326.
44.
VALLADEAUJ., DUVERT-FRANCES.V, PINJ.J., KLEIJMEERM.J., AIT-YAHIAS., RAVELO., VINCENTC., VEGAF., HELMSA., GORMAND., et al. (2001). Immature human dendritic cells express asialoglycoprotein receptor isoforms for efficient receptor-mediated endocytosis. J. Immunol., 167, 5767–5774.
45.
VORAH.H., PATELN.A., RAJVIKK.N., MEHTAS.V., BRAHMBHATTB.V., SHAHM.J., SHUKLAS.N., and SHAHP.M. (2009). Cytokeratin and vimentin expression in breast cancer. Int. J. Biol. Markers., 24, 38–46.
46.
WHITEHEADK.A., LANGERR., and ANDERSOND.G. (2009). Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov., 8, 129–138.
47.
WILLIAMSA.A., HIGGINSJ.P., ZHAOH., LJUNBERGB., and BROOKSJ.D. (2009). CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC Clin. Pathol. 9,9.
48.
ZHAOY., YANQ., LONGX., CHENX., and WANGY. (2008). Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem. Funct., 26, 571–577.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
